Bauernfeind A, Hörl G, Przyklenk B
Max von Pettenkofer Institute, University of Munich.
Infection. 1987;15 Suppl 5:S232-5. doi: 10.1007/BF01643195.
Trimethoprim-sulfamethoxazole in vitro activity was compared with ampicillin, tetracycline, sulfonamide and trimethoprim against isolates of 24 gram-negative and 11 gram-positive species. The incidence of more than 10% of strains with minimal inhibitory concentrations above 32 mg/l was restricted to Escherichia coli, Shigella spp., Klebsiella pneumoniae, Providencia rettgeri, Morganella morganii, methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Occasionally, Streptococcus pneumoniae and Haemophilus influenzae strains with MICs above 32 mg/l were identified. Co-trimoxazole in vitro activity was superior to the comparative drugs for the majority of species. Co-trimoxazole remains an active combination against major pathogens of infections of the upper and lower respiratory, urinary tract and enteric infections with a still low incidence of resistant organisms.
将甲氧苄啶-磺胺甲恶唑的体外活性与氨苄西林、四环素、磺胺类药物和甲氧苄啶针对24种革兰氏阴性菌和11种革兰氏阳性菌的分离株进行了比较。最低抑菌浓度高于32mg/l的菌株发生率超过10%的情况仅限于大肠杆菌、志贺氏菌属、肺炎克雷伯菌、雷氏普罗威登斯菌、摩根氏摩根菌、耐甲氧西林金黄色葡萄球菌和表皮葡萄球菌。偶尔也会鉴定出最低抑菌浓度高于32mg/l的肺炎链球菌和流感嗜血杆菌菌株。对于大多数菌种,复方新诺明的体外活性优于对照药物。复方新诺明仍然是针对上、下呼吸道感染、尿路感染和肠道感染的主要病原体的一种活性组合,耐药菌的发生率仍然较低。